PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Mirabegron - Overactive bladder (adults)

PAD Profile : Mirabegron - Overactive bladder (adults) Important

Keywords :
OAB, urge incontinence, urinary incontinence, urinary frequency, LUTS, over-active bladder, urinary urgency
Brand Names Include :
Betmiga
Important Information :
Solifenacin is 1st line. Mirabegron for use when antimuscarinics are contraindicated, patients with CNS adverse effects or patients requiring a more potent treatment.

Traffic Light Status

Status 1 of 1.

Status :
Green (see narrative)
Formulations :
  • Not Specified
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

The following guidelines are available for this indication.

Other Drugs

Other Indications

No indications returned.

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 March 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The APC supports patients in trialling a treatment break of their overactive bladder medicines.

A "Leaflet for trial of stopping mirabegron" can be found in the documents section.

06 September 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

Solifenacin is the 1st line treatment option.

Mirabegron is reserved for patients:

  • in whom an antimuscarininc is contraindicated
  • requiring (and can tolerate) a more potent treatment
  • 3rd line where experiencing CNS adverse effects (confusion, drowsiness, hallucinations)

See Selection Tool for locally agreed OAB treament options

Associated BNF Codes

07. Obstetrics, Gynaecology and Urinary-Tract Disorders
07.04.02. Drugs for urinary frequency enuresis and incontinence
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More